StreetInsider.com News Articles

AsymBio Establishes Integrated Technology Platforms Spanning the Full Biopharmaceutical Development Lifecycle

Tue, 10 Feb 2026 09:00:00 -0400

SHANGHAI, Feb. 10, 2026 /PRNewswire/ -- AsymBio, a subsidiary of Asymchem Group (stock code: 002821.SZ / 6821.HK), announced that it has established integrated technology platforms spanning the full biopharmaceutical development lifecycle. Through its end-to-end service capabilities, the company provides streamlined, integrated workflows for client programs from early development to commercial manufacturing.

AsymBio Establishes Integrated Technology Platforms Spanning the Full Biopharmaceutical Development Lifecycle

Tue, 10 Feb 2026 09:00:00 -0400

AsymBio Establishes Integrated Technology Platforms Spanning the Full Biopharmaceutical Development Lifecycle

Tue, 10 Feb 2026 09:00:00 -0400

AsymBio Establishes Integrated Technology Platforms Spanning the Full Biopharmaceutical Development Lifecycle

Tue, 10 Feb 2026 09:00:00 -0400

AsymBio Establishes Integrated Technology Platforms Spanning the Full Biopharmaceutical Development Lifecycle

Tue, 10 Feb 2026 09:00:00 -0400

AsymBio Establishes Integrated Technology Platforms Spanning the Full Biopharmaceutical Development Lifecycle

Tue, 10 Feb 2026 09:00:00 -0400

AsymBio Establishes Integrated Technology Platforms Spanning the Full Biopharmaceutical Development Lifecycle

Tue, 10 Feb 2026 09:00:00 -0400

AsymBio Establishes Integrated Technology Platforms Spanning the Full Biopharmaceutical Development Lifecycle

Tue, 10 Feb 2026 09:00:00 -0400

AsymBio Commences Commercial Operations at Fengxian Base, Strengthening Global Biopharmaceutical CDMO Capabilities

Mon, 08 Dec 2025 00:00:00 -0400

SHANGHAI, Dec. 8, 2025 /PRNewswire/ -- AsymBio, a technology-driven global Contract Development and Manufacturing Organization (CDMO) and a subsidiary of Asymchem Group (stock code: 002821.SZ / 6821.HK), today announced the official start of commercial production at its Shanghai Fengxian Commercial Manufacturing Base. This milestone expands AsymBio's integrated, end-to-end biologics CDMO services and reinforces its commitment to accelerating the commercialization of innovative therapies worldwide.

AsymBio Commences Commercial Operations at Fengxian Base, Strengthening Global Biopharmaceutical CDMO Capabilities

Mon, 08 Dec 2025 00:00:00 -0400

AsymBio Commences Commercial Operations at Fengxian Base, Strengthening Global Biopharmaceutical CDMO Capabilities

Mon, 08 Dec 2025 00:00:00 -0400

AsymBio Commences Commercial Operations at Fengxian Base, Strengthening Global Biopharmaceutical CDMO Capabilities

Mon, 08 Dec 2025 00:00:00 -0400

AsymBio Commences Commercial Operations at Fengxian Base, Strengthening Global Biopharmaceutical CDMO Capabilities

Mon, 08 Dec 2025 00:00:00 -0400

AsymBio Commences Commercial Operations at Fengxian Base, Strengthening Global Biopharmaceutical CDMO Capabilities

Mon, 08 Dec 2025 00:00:00 -0400

AsymBio Commences Commercial Operations at Fengxian Base, Strengthening Global Biopharmaceutical CDMO Capabilities

Mon, 08 Dec 2025 00:00:00 -0400

AsymBio Commences Commercial Operations at Fengxian Base, Strengthening Global Biopharmaceutical CDMO Capabilities

Mon, 08 Dec 2025 00:00:00 -0400

Asymchem’s Fully Automated Peptide Production Lines Set New Benchmarks as Large-Scale Capacity Continues to Grow

Tue, 12 Nov 2024 11:00:00 -0400

MORRISVILLE, N.C.--(BUSINESS WIRE)-- To facilitate large-scale production of peptide drugs, Asymchem (stock codes: 002821.SZ/6821.HK), a leading global pharmaceutical contract development and manufacturing organization (CDMO), has achieved fully automated manufacturing.

One initial hurdle was equipment scale-up. In particular, the optimal suspension and mixing of resin with reactants and the structural design of the synthesizer required careful attention. To address this, Asymchem’s Chemical Engineering Department (CED) utilized advanced simulation techniques and experimental validation to finalize the solid-phase synthesizer design and define the stirring paddles’ structural characteristics. The new structure is in the patent application process and

Asymchem’s Fully Automated Peptide Production Lines Set New Benchmarks as Large-Scale Capacity Continues to Grow

Tue, 12 Nov 2024 11:00:00 -0400

Asymchem’s Fully Automated Peptide Production Lines Set New Benchmarks as Large-Scale Capacity Continues to Grow

Tue, 12 Nov 2024 11:00:00 -0400

Asymchem’s Fully Automated Peptide Production Lines Set New Benchmarks as Large-Scale Capacity Continues to Grow

Tue, 12 Nov 2024 11:00:00 -0400

Asymchem’s Fully Automated Peptide Production Lines Set New Benchmarks as Large-Scale Capacity Continues to Grow

Tue, 12 Nov 2024 11:00:00 -0400

Asymchem’s Fully Automated Peptide Production Lines Set New Benchmarks as Large-Scale Capacity Continues to Grow

Tue, 12 Nov 2024 11:00:00 -0400

Asymchem’s Fully Automated Peptide Production Lines Set New Benchmarks as Large-Scale Capacity Continues to Grow

Tue, 12 Nov 2024 11:00:00 -0400

Asymchem’s Fully Automated Peptide Production Lines Set New Benchmarks as Large-Scale Capacity Continues to Grow

Tue, 12 Nov 2024 11:00:00 -0400

Building a World-Class Synthetic Biology Lab: Asymchem’s Self-Developed STAR System Empowers Protein Design

Wed, 06 Nov 2024 11:00:00 -0400

MORRISVILLE, N.C.--(BUSINESS WIRE)-- Asymchem (stock code: 002821.SZ/6821.HK), a leading global contract development and manufacturing organization (CDMO), has created an artificial intelligence (AI) platform to address key challenges in protein design. This platform, known as STAR (Sequence Recommendation via Artificial Intelligence), was successfully developed by Asymchem’s Center of Synthetic Biology Technology (CSBT) and AI team. The team published a paper titled “STAR: A Web Server for Assisting Directed Protein Evolution with Machine Learning” in ACS Omega, detailing the system’s ability to integrate multiple machine learning models and sequence encoding methods.

One